New microneedle vaccine shows promise in pre-clinical trials
A single-use, self-administered microneedle vaccine has been developed to provide immunisation against infectious diseases.
List view / Grid view
A single-use, self-administered microneedle vaccine has been developed to provide immunisation against infectious diseases.
A new nasal spray with ingredients already approved for use in humans could be used to protect people against COVID-19.
Report reveals global pharma supply chain leaders are afraid of the vulnerabilities in the end-to-end supply chain as the COVID-19 pandemic continues.
At Lonza, we have developed our CFS 1200® capsule filling and sealing machine as part of our Lonza Engine™ portfolio. Used with our Capsugel® capsules, pharmacies can automate this process to optimise operations and accuracy. This fact sheet will introduce you to its handling and sealing capabilities, key benefits, performance…
An overview on the role of BPOG extractables data in the effective adoption of single-use systems in biomanufacturing
Take our 10-question quiz to find out how efficient your Total Organic Carbon (TOC) monitoring programme is for your applications.
Innocoll Holdings Limited has announced the commercial launch of the XARACOLL® (bupivacaine HCI) implant, a non-opioid treatment for acute post-surgical pain for up to 24 hours in adults following open inguinal hernia repair.
A major challenge in achieving clinically relevant oral delivery of biologics is overcoming the multiple physiological barriers in the gastrointestinal tract. In this article Nikki Withers discusses these challenges with Shawn Davis, Head of Drug Delivery, BioPharmaceuticals Development, R&D at AstraZeneca, who shares some of the latest advances in drug…
The study will establish whether NOviricid can improve COVID-19 patient outcomes and survival in 840 recently diagnosed African American patients with comorbidities.
A Phase I clinical trial of remestemcel-L delivered by an endoscope to patients with Crohn’s disease and ulcerative colitis has commenced.
The increasing use of subcutaneous administration stems from the significant advances in biological drug development, as well as the rising trend of self-administration.
Extractables studies for chromatography resins based on the adapted requirements of the USP support risk evaluation for chromatography steps.
The first-in-human clinical trial of nanoformed piroxicam will begin in late 2020, with results expected by mid-2021.
A new report has shown that through the COVID-19 pandemic, the global nasal drug delivery technology market is predicted to increase.
Introduction to BioPhorum (BPOG) raw materials risk assessments tool and an overview on risk assessment regulations for raw materials.